Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 7:37 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 313–336 of 20,633 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Blood sample Clear all
Terminated Phase 2Phase 3 Interventional

Assessment of the Treatment of Severely Burned With Anabolic Agents on Clinical Outcomes, Recovery and Rehabilitation

NCT00675714
View directory record Official record
Conditions
Burns
Interventions
Stable Isotope Infusion Study, Collection of blood and tissues, Radiology testing: Dual-energy X-ray absorptiometry (DEXA), ultrasound, MRI, Humatrope, Ketoconazole, Oxandrolone, Propranolol, Oxandrolone and propranolol combined, Humatrope and propranolol combined, Placebo, Exercise--Hospital supervised intensive exercise program, Home exercise program
Procedure · Drug · Behavioral
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
Up to 80 Years
Enrollment
1,126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2019
U.S. locations
1
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 29, 2019 · Synced Oct 19, 2026, 7:37 AM EDT
Not listed Not applicable Interventional

The Usability, Acceptability, and Perceived Value of the Cornerstones4Care Powered by Glooko App

NCT03222284
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Cornerstones4Care Powered by Glooko App
Device
Lead sponsor
Healthcare Innovation Technology Lab
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 26, 2017 · Synced Oct 19, 2026, 7:37 AM EDT
Completed Phase 1 Interventional

Alpha-Amino-3-Hydroxy-5-Methyl-4- Isoxazole Propionic Acid Receptor Components of the Anti-Depressant Ketamine Response, Pilot Trial

NCT03367533
View directory record Official record
Conditions
Depressive Disorder, Major, Post Traumatic Stress Disorder, Bipolar Disorder
Interventions
Ketamine, Perampanel, Placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 65 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Feb 7, 2025 · Synced Oct 19, 2026, 7:37 AM EDT
Completed Phase 2 Interventional Results available

VIGABatrin in Post-anoxic STATus Epilepticus - Phase IIa

NCT04772547
View directory record Official record
Conditions
Status Epilepticus, Electrographic, Coma
Interventions
Vigabatrin Only Product
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 80 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Jul 23, 2024 · Synced Oct 19, 2026, 7:37 AM EDT
Not yet recruiting No phase listed Observational Accepts healthy volunteers

Collecting Data on Retinal Blood Blood Flow and Blood Vessel Shape/Appearance Using an Investigational Device, XyCAM CRE, and to Then Compare Those Images With Images Collected From a Patient's Routine Clinical Examination.

NCT07641738
View directory record Official record
Conditions
Microvascular Disease, Retinal Disease
Interventions
XyCAM CRE Imaging
Device
Lead sponsor
Stuart Terry Eye Associates
Other
Eligibility
21 Years to 100 Years
Enrollment
350 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2030
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Oct 19, 2026, 7:37 AM EDT
Completed Phase 1 Interventional

A Dose Titration of Droxidopa in Patients With Spinal Cord Injury

NCT01354158
View directory record Official record
Conditions
Spinal Cord Injury, Hypotension
Interventions
Droxidopa
Drug
Lead sponsor
Bronx VA Medical Center
Federal
Eligibility
18 Years to 65 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Jul 30, 2013 · Synced Oct 19, 2026, 7:37 AM EDT
Completed Phase 1 Interventional

Phase I Pilot Study of Total-Body Irradiation, Anti-Thymocyte Globulin and Cyclophosphamide Followed By Syngeneic or Autologous Peripheral Blood Stem Cell Transplantation in Patients With Multiple Sclerosis

NCT00014755
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
anti-thymocyte globulin, cyclophosphamide, filgrastim, prednisone, peripheral blood stem cell transplantation, irradiation
Drug · Procedure
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years to 60 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1997
U.S. locations
6
States / cities
Duarte, California • Denver, Colorado • St Louis, Missouri + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 19, 2026, 7:37 AM EDT
Completed Phase 2 Interventional Results available

Adverse Effects of Red Blood Cell Transfusions: A Unifying Hypothesis (Aim 3)

NCT02280655
View directory record Official record
Conditions
Cardiovascular Diseases
Interventions
Storage-aged red blood cells (saRBCs) units, Fresh red blood cells units
Biological
Lead sponsor
Emory University
Other
Eligibility
18 Years to 80 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Apr 11, 2016 · Synced Oct 19, 2026, 7:37 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Validating eNose Measurement of Daily Fiber Intake

NCT05634044
View directory record Official record
Conditions
Dietary Fiber
Interventions
eNose Device
Device
Lead sponsor
Rush University Medical Center
Other
Eligibility
21 Years to 65 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 29, 2024 · Synced Oct 19, 2026, 7:37 AM EDT
Completed Phase 3 Interventional Results available

An Investigational Immuno-therapy Study of Nivolumab Compared to Sorafenib as a First Treatment in Patients With Advanced Hepatocellular Carcinoma

NCT02576509
View directory record Official record
Conditions
Hepatocellular Carcinoma
Interventions
Nivolumab, Sorafenib
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
743 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2024
U.S. locations
17
States / cities
Birmingham, Alabama • Los Angeles, California • San Francisco, California + 10 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2025 · Synced Oct 19, 2026, 7:37 AM EDT
Completed Phase 2 Interventional Results available

A Study of Brentuximab Vedotin and CHP in Frontline Treatment of PTCL With Less Than 10% CD30 Expression

NCT04569032
View directory record Official record
Conditions
Peripheral T-cell Lymphoma
Interventions
brentuximab vedotin, cyclophosphamide, doxorubicin, prednisone
Drug
Lead sponsor
Seagen, a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years and older
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
43
States / cities
Birmingham, Alabama • Stanford, California • Aurora, Colorado + 25 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Oct 19, 2026, 7:37 AM EDT
Completed Not applicable Interventional Results available

MBCT Via Group Videoconferencing for Acute Coronary Syndrome Patients With Depressive Symptoms: A Pilot RCT

NCT04799899
View directory record Official record
Conditions
Cardiovascular Diseases, Acute Coronary Syndrome, Depression
Interventions
Adapted MBCT, Cardiac Health Enhancement
Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
35 Years to 80 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 29, 2025 · Synced Oct 19, 2026, 7:37 AM EDT
Terminated Phase 2 Interventional Results available

Bortezomib (Velcade) With Standard Chemotherapy for Relapsed or Refractory Follicular Lymphoma

NCT00510887
View directory record Official record
Conditions
Lymphoma, Follicular
Interventions
Bortezomib, Rituximab, Fludarabine, Mitoxantrone, Dexamethasone
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated May 12, 2014 · Synced Oct 19, 2026, 7:37 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Lung Cancer Risk Assessment and Etiology

NCT06328621
View directory record Official record
Conditions
Lung Carcinoma
Interventions
Biospecimen Collection, Computed Tomography, Electronic Health Record Review, Survey Administration
Procedure · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
109 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2026
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Mar 18, 2026 · Synced Oct 19, 2026, 7:37 AM EDT
Completed Not applicable Interventional Results available

Cardiovascular Effects in Psoriasis Patients Treated With Adalimumab.

NCT01320293
View directory record Official record
Conditions
Psoriasis
Interventions
Adalimumab 40 MG/0.8 ML Subcutaneous Solution [HUMIRA]
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 55 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 26, 2016 · Synced Oct 19, 2026, 7:37 AM EDT
Completed Phase 2 Interventional Results available

Clonidine Versus Adenosine to Treat Neuropathic Pain

NCT00349921
View directory record Official record
Conditions
Pain
Interventions
clonidine, adenosine, placebo
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
Not listed
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
2
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 10, 2018 · Synced Oct 19, 2026, 7:37 AM EDT
Completed Not applicable Interventional Results available

Next-Generation Sequencing for Pathogen Detection and Quantification in Children With Musculoskeletal Infections

NCT03846804
View directory record Official record
Conditions
Musculoskeletal Infection, Acute Hematogenous Osteomyelitis, Septic Arthritis, Osteomyelitis, Pyomyositis
Interventions
Karius Test
Diagnostic Test
Lead sponsor
Indiana University
Other
Eligibility
6 Months to 18 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Dec 1, 2023 · Synced Oct 19, 2026, 7:37 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Ovarian Morphology and Theca Cell Androgen Production in Women With Polycystic Ovary Syndrome (PCOS)

NCT02145247
View directory record Official record
Conditions
Polycystic Ovary Syndrome
Interventions
hCG
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 37 Years · Female only
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2018
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Aug 12, 2019 · Synced Oct 19, 2026, 7:37 AM EDT
Recruiting Not applicable Interventional

Post Approval Study for Treatment of Drug-resistant Adult and Pediatric Primary FSGS Using the LIPOSORBER® LA-15 System

NCT04065438
View directory record Official record
Conditions
Focal Segmental Glomerulosclerosis
Interventions
LIPOSORBER® LA-15
Device
Lead sponsor
Kaneka Medical America LLC
Industry
Eligibility
Up to 75 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2029
U.S. locations
10
States / cities
Loma Linda, California • Wilmington, Delaware • Grand Rapids, Michigan + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2026 · Synced Oct 19, 2026, 7:37 AM EDT
Completed Phase 3 Interventional

Percutaneous Catheter Decompression in the Treatment of Elevated Intra-abdominal Pressure

NCT01230255
View directory record Official record
Conditions
Compartment Syndromes
Interventions
Percutaneous catheter drainage
Procedure
Lead sponsor
Orlando Regional Medical Center
Other
Eligibility
15 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Oct 29, 2010 · Synced Oct 19, 2026, 7:37 AM EDT
Completed Phase 4 Interventional Results available

Evaluating Blood Glucose Levels During Infusion With HepaGam B (HBIG) in Post-liver Transplant Patients

NCT00998426
View directory record Official record
Conditions
Hepatitis B
Interventions
glucose monitoring before and after HepaGam B administration, HepaGam B (Hepatitis B Immune Globulin (HBIG))
Procedure · Biological
Lead sponsor
Georgetown University
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Sep 28, 2015 · Synced Oct 19, 2026, 7:37 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

This Study Evaluates the ALPCO Syphilis-T and Syphilis-NT CLIA Kits for Detecting Syphilis Antibodies in Serum and Plasma. Samples From At-risk, HIV-positive, Pregnant, and Healthy Individuals Will Assess Assay Performance Versus Established Comparator Tests.

NCT07089836
View directory record Official record
Conditions
Treponema Pallidum, Treponema Pallidum Infection, Syphilis Infection, Serum, Plasma, Blooddraw, Sexually Transmitted Infection (STI)
Interventions
ALPCO Syphilis-T, ALPCO Syphilis-NT CLIA Kits
Device
Lead sponsor
American Laboratory Products Company
Industry
Eligibility
13 Years and older
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
6
States / cities
Lancaster, California • Los Angeles, California • North Miami, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Oct 19, 2026, 7:37 AM EDT
Recruiting No phase listed Observational

Evaluation of Patients With Non-obstructive Coronary Arteries

NCT00823563
View directory record Official record
Conditions
Chest Pain, Ischemia
Interventions
30 cc blood draw, Intravascular ultrasound (IVUS), Coronary pressure/flow wire testing, Coronary pressure/flow testing: Acetycholine challenge, Procedure: Coronary pressure/flow testing: Nitroglycerin challenge, Procedure: Procedure: Coronary pressure/flow testing: Adenosine challenge
Procedure
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2047
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jun 5, 2025 · Synced Oct 19, 2026, 7:37 AM EDT
Completed Phase 1 Interventional

Study of Omalizumab as Adjuvant Therapy in Chemotherapy Desensitization

NCT02118987
View directory record Official record
Conditions
Drug Allergy
Interventions
Omalizumab
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 22, 2018 · Synced Oct 19, 2026, 7:37 AM EDT